Lanean...

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer

Mutational testing has moved to the forefront as an integral component in the management of patients with non-small cell lung cancer (NSCLC). Currently there are three targeted therapies (erlotinib, afatinib, and crizotinib) approved by the Food and Drug Administration (FDA) to treat patients with s...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lammers, Philip E., Lovly, Christine M., Horn, Leora
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4151469/
https://ncbi.nlm.nih.gov/pubmed/24453288
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!